• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

Safety and Efficacy of AstraZeneca Oxford’s COVID-19 Vaccine

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • AstraZeneca Oxford’s ChAdOx1 nCoV-19 vaccine uses an adenoviral vector ChAdOx1 that contains the SARS-CoV-2 structural surface glycoprotein antigen
  • Voysey et al. (Lancet, 2020) evaluated the safety and efficacy of the AstraZeneca Oxford’s ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials

METHODS:

  • Pooled data from four ongoing blinded, randomized, controlled trials (COV001-3 are single blind | COV005 is double blind)
    • COV001: Phase 1/2; UK
    • COV002: Phase 2/3; UK
    • COV003: Phase 3; Brazil
    • COV005: Phase 1/2; South Africa
  • Participants
    • ≥18 years and older
  • Interventions
    • ChAdOx1 nCoV-19 vaccine
      • Standard dose/Standard dose (SD/SD) cohort: 2 doses containing 5 × 1010 viral particles
      • Low dose/Standard dose (LD/SD) cohort: Subset in the UK trial received a half dose as their first dose and a standard dose as their second dose
    • Control
      • Meningococcal group A, C, W, and Y conjugate vaccine OR saline

Note: The lower dose (LD) was noted during quality control procedures (for COV002 trial) and the protocol was amended following review and approval

  • Study design
    • Analysis was according to treatment received, with a data cutoff on Nov 4, 2020
    • Vaccine efficacy was calculated as 1-relative risk derived from a robust Poisson regression model adjusted for age
  • Primary outcomes
    • Primary efficacy analysis: symptomatic COVID-19 in seronegative participants with a positive PCR test >14 days after a second dose of vaccine

RESULTS:

  • 23,848 participants enrolled | 11,636 were included in the interim primary efficacy analysis

Efficacy

  • SD/SD vaccine efficacy: 62.1% (95% CI, 41.0 to 75.7%)
    • ChAdOx1 nCoV-19 group: 0.6% developed COVID-19
    • Control: 1.6% developed COVID-19
  • LD/SD vaccine efficacy: 90.0% (95% CI, 67.4 to 97.0%)
    • ChAdOx1 nCoV-19 group: 0.2% developed COVID-19
    • Control group: 2.2% developed COVID-19
  • Overall vaccine efficacy across both groups was: 70.4% (95% CI, 54.8 to 80.6%)
    • ChAdOx1 nCoV-19 group: 0.5% developed COVID-19
    • Control group: 1.7% developed COVID-19

Safety

  • From 21 days after the first dose, there were 10 people hospitalized for COVID-19, all of which were in the control arm
    • Severe COVID-19: 2 participants
    • Deaths: 1 participant
  • During 74,341 person-months of safety follow-up (median follow-up 3.4 months, IQR 1.3 to 4.8 months) there were 175 severe adverse events among 168 participants
    • ChAdOx1 nCoV-19 group: 84 events
    • Control group: 91 events
  • 3 adverse events were classified as possibly related to the vaccine
    • ChAdOx1 nCoV-19 group: 1 participant
    • Control group: 1 participant
    • Still masked: 1 participant

CONCLUSION:

  • The AstraZeneca Oxford SARS-CoV-2 vaccine, the first peer-review study of a viral-vectored coronavirus, is safe and efficacious for the prevention of symptomatic COVID-19
    • Overall efficacy was 70.4%
    • Results were generalizable across diverse settings
    • Additional benefit of a viral-vectored vaccine is the use of routine refrigerated cold chain vs ultra-low temperature freezers required for mRNA vaccines
  • The authors address the increased efficacy of LD/SD dosing vs SD/SD and state

Efficacy of 90.0% seen in those who received a low dose as prime in the UK was intriguingly high compared with the other findings in the study

Although there is a possibility that chance might play a part in such divergent results, a similar contrast in efficacy between the LD/SD and SD/SD recipients with asymptomatic infections provides support for the observation

Learn More – Primary Sources:

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Comment: Oxford–AstraZeneca COVID-19 vaccine efficacy

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

Safety and Efficacy Data of BNT162b2 COVID-19 Vaccine
Do Warmer Temperatures Decrease the Incidence of COVID-19?
Surgical Masks Reduce Viral Shedding

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site